Drugs, Health Technologies, Health Systems

Reimbursement Recommendation

Ropeginterferon Alfa-2b (Besremi)

Indication: For the treatment of adults with polycythemia vera

Sponsor: FORUS Therapeutics, Inc.

Recommendation: Reimburse with conditions

Summary

What Is the Reimbursement Recommendation for Besremi?

Canada’s Drug Agency (CDA-AMC) recommends that Besremi be reimbursed by public drug plans for the treatment of adult patients with polycythemia vera (PV) requiring cytoreductive therapy if certain conditions are met.

Why Did CDA-AMC Recommend Reimbursement?

The pan-Canadian Oncology Drug Review Expert Review Committee (pERC) determined that it is uncertain whether Besremi demonstrates acceptable clinical value versus hydroxyurea, peginterferon alfa-2a, and ruxolitinib in patients with PV requiring cytoreductive therapy. Given that Besremi is expected to be an alternative treatment to hydroxyurea, acceptable clinical value refers to at least comparable value versus hydroxyurea.

Evidence from a clinical trial failed to show that Besremi is noninferior to hydroxyurea at 12 months in patients with PV requiring cytoreductive therapy. However, the evidence from the completed long-term extension study suggested numerical improvements in disease response rates, complete hematological response, molecular response, and change in JAK2 allele burden when Besremi was compared to best available therapy. Evidence from an indirect treatment comparison showed that the complete hematological response was similar between Besremi and peginterferon alfa-2a in patients with PV.

pERC has established that there is significant unmet clinical need for additional cytoreductive treatment options for PV. Currently, there are limited treatment options with hydroxyurea used off-label as the main first-line option. There are challenges with hydroxyurea as patients may develop intolerance or resistance; hydroxyurea may be unsuitable for those of reproductive age; and there have been recent supply shortages, rendering the need for more treatment options for patients. pERC concluded that Besremi addresses a significant unmet need to a degree that justifies a positive recommendation despite the uncertainty in clinical value.

Which Patients Are Eligible for Coverage?

Besremi should only be reimbursed for the treatment of adult patients with PV requiring cytoreductive therapy if they are aged 18 years or older, with a confirmed diagnosis of PV and have good performance status.

For adult patients who require cytoreductive treatment but have not received any prior treatment, they must meet 1 of the following conditions: aged older than 60 years, previously documented cardiovascular or thromboembolic event(s), poor tolerance to phlebotomy, progressive splenomegaly, elevated platelet counts or thrombocytosis, or leukocytosis.

For adult patients who require cytoreductive treatment and are currently treated or have been pretreated with hydroxyurea, they must meet 1 of the following conditions: documented resistance to hydroxyurea or intolerance to hydroxyurea.

What Are the Conditions for Reimbursement?

Besremi should not be reimbursed if the patient experiences disease progression or unacceptable toxicity. Besremi should be prescribed by a clinician experienced in the diagnosis and management of PV. The cost of Besremi should be negotiated so that it does not exceed the cost of treatment with the least costly cytoreductive treatment reimbursed for PV. Important budget impact considerations and organizational implications must be addressed for health systems to be able to adopt Besremi.

Review Background

Highlights of Input From Interested Parties

The patient groups (Heal Canada, the Leukemia & Lymphoma Society of Canada, and the Canadian MPN Network) noted the following regarding impacts of the disease, unmet needs, and important outcomes:

The clinician groups (Canadian MPN Group and Ontario Health [Cancer Care Ontario] Hematology Cancer Drug Advisory Committee) and the clinical experts consulted by CDA-AMC noted the following regarding unmet needs arising from the disease and place in therapy for the drug under review:

The participating public drug programs provided input regarding considerations for initiation of therapy.

Recommendation

With a vote of 11 in favour to 4 against, pERC recommends that ropeginterferon alfa-2b be reimbursed for the treatment of adult patients with PV requiring cytoreductive therapy, only if the conditions listed in Table 1 are met.

Table 1: Reimbursement Conditions and Reasons

Reimbursement condition

Reason

Implementation guidance

Initiation

1. Treatment with ropeginterferon alfa-2b should be reimbursed when initiated in patients with PV requiring cytoreductive treatment who meet the following criteria:

1.1. aged 18 years or older

1.2. confirmed diagnosis of polycythemia vera

1.3. good performance status.

Evidence from the PROUD-PV and LTE CONTINUATION-PV trials demonstrated that treatment with ropeginterferon alfa-2b resulted in a clinically meaningful benefit in patients with these characteristics.

Patients with an ECOG PS score of greater than 2 were excluded from the trial.

Condition 1.3: pERC agreed with the clinical experts consulted by CDA-AMC that patients with ECOG PS scores of greater than 2 should not be considered eligible for treatment with ropeginterferon alfa-2b.

2. Adult patients who require cytoreductive treatment but have not received any treatment previously, should meet 1 or more of the following:

2.1. aged older than 60 years

2.2. previously documented cardiovascular or thromboembolic event(s)

2.3. poor tolerance to phlebotomy

2.4. progressive splenomegaly

2.5. elevated platelet counts or thrombocytosis

2.6. leukocytosis.

This is to align with the clinical evidence from the PROUD-PV and LTE CONTINUATION-PV trials.

Condition 2.3: In the PROUD-PV trial, poor tolerance was defined as 1 of the following:

  • phlebotomy-related or procedure-related adverse event causing significant adverse impact on the patient and limiting ability to apply phlebotomy with the intention to keep hematocrit < 45%

  • frequent need for phlebotomy of more than 1 phlebotomy within the last 3 months.

Condition 2.4: In the PROUD-PV trial, progressive splenomegaly was defined as de novo appearance of a palpable spleen or appearance of the symptoms, related to the enlarged spleen (e.g., pain, early satiety, and so forth), with confirmed size increase.

Condition 2.5: In the PROUD-PV trial, an elevated platelet count was defined as platelet counts greater than 1,000 × 109/L (for 2 measurements within 1 week).

Condition 2.6: In the PROUD-PV trial, leukocytosis was defined as white blood count > 10 × 109/L for 2 measurements within 1 week.

3. Adult patients who require cytoreductive treatment and are currently treated or have been pretreated with hydroxyurea, should have 1 of the following:

3.1. documented resistance to hydroxyurea

3.2. intolerance to hydroxyurea.

This is to align with the clinical evidence from the PROUD-PV and CONTINUATION-PV trials.

The documented resistance or intolerance to hydroxyurea should be determined by the treating physician.

pERC agreed with the clinical experts that for patients with PV currently receiving first-line hydroxyurea for cytoreductive therapy, switching to ropeginterferon alfa-2b for a limited period at the time of implementation would be reasonable, provided these patients have documented resistance or intolerance to hydroxyurea.

Discontinuation

4. Treatment should be discontinued upon the occurrence of either of the following:

4.1. disease progression

4.2. unacceptable toxicity.

Patients in the PROUD-PV and CONTINUATION-PV trials discontinued treatment upon disease progression and unacceptable toxicity.

—

Prescribing

5. Ropeginterferon alfa-2b should be prescribed by a clinician experienced in the diagnosis and management of PV.

This is meant to ensure that ropeginterferon alfa-2b is prescribed for appropriate patients.

—

Pricing

6. The cost of ropeginterferon alfa-2b should be negotiated so that it does not exceed the cost of treatment with the least costly cytoreductive treatment reimbursed for the same indication.

Based on the committee’s assessment of the evidence, ropeginterferon alfa-2b is expected to have broadly comparable benefits and harms compared with hydroxyurea. The comparative effectiveness of ropeginterferon alfa-2b with peginterferon alfa-2a is uncertain. Therefore, the total cost of ropeginterferon alfa-2b should be no more than the least costly cytoreductive treatment reimbursed for this indication.

—

Feasibility of adoption

7. The economic feasibility of adoption of ropeginterferon alfa-2b must be addressed.

At the submitted price, the incremental budget impact of ropeginterferon alfa-2b is expected to be greater than $40 million in years 2 and 3.

—

CDA-AMC = Canada’s Drug Agency; ECOG PS = Eastern Cooperative Oncology Group Performance Status; LTE = long-term extension; pERC = pan-Canadian Oncology Drug Review Expert Review Committee; PV = polycythemia vera.

Rationale for the Recommendation

Clinical Value

Based on the totality of the clinical evidence, pERC concluded that it is uncertain whether ropeginterferon alfa-2b demonstrates acceptable clinical value compared with appropriate comparators including hydroxyurea, peginterferon alfa-2a, and ruxolitinib. Given that ropeginterferon alfa-2b is expected to be an alternative to hydroxyurea, acceptable clinical value refers to at least comparable value versus hydroxyurea.

Evidence from 1 phase III randomized controlled trial (PROUD-PV; N = 257) showed at 12 months of treatment that the disease response rate was 21.3% for the ropeginterferon alfa-2b group and 27.6% for the hydroxyurea group (between-group difference = -███ [95% confidence interval [CI], █████ to ███]). Ropeginterferon alfa-2b failed to demonstrate noninferiority to hydroxyurea at 12 months because the lower bound of the 95% CI exceeded the noninferiority margin of −10.5%.

Evidence from the PROUD-PV trial showed that compared with hydroxyurea, treatment with ropeginterferon alfa-2b for 12 months likely resulted in similar clinical benefit for adult patients with PV in terms of the proportions of patients achieving disease response (between-group difference = █████%; 95% CI, ██████ to ████), durable disease response (between-group difference = █████%; 95% CI, █████ ██ ████), and complete hematological response (between-group difference = −3.02%; 95% CI, −15.55% to 9.52%). Data from the PROUD-PV trial also indicated that compared with hydroxyurea, treatment with ropeginterferon alfa-2b may result in little to no clinically important difference in health-related quality of life (HRQoL) (as measured by change in the EQ visual analogue scale (VAS) from baseline to 12 months) among adult patients with PV. In the PROUD-PV trial, the mean number of phlebotomies per patient and visit during the study was numerically higher among patients in the ropeginterferon alfa-2b group (0.19; range, 0 to 10) versus patients in the hydroxyurea group (0.16; range, 0 to 12).

Key limitations of the PROUD-PV trial include its open-label design and high rates of missing data for the HRQoL results. According to the clinical experts consulted for this review, a follow-up period of 12 months is insufficient to observe the full treatment response of ropeginterferon alfa-2b. In addition, an important generalizability concern is that the slow titration dose escalation of ropeginterferon alfa-2b used in the PROUD-PV trial does not align with current practice where a more rapid dose escalation may achieve faster hematological responses.

Evidence from the completed long-term extension of the PROUD-PV trial (the CONTINUATION-PV study) suggested that at 36 months, ropeginterferon alfa-2b was associated with numerical improvements in disease response rates, complete hematological response, molecular response, and change in JAK2 allele burden, when compared with best available therapy. Similar changes in EQ VAS from baseline to 36 months were observed for the ropeginterferon alfa-2b and best available therapy groups. After more than 7 years of follow-up, treatment with ropeginterferon alfa-2b was associated with a higher probability of event-free survival (defined as an absence of thrombotic events, myelofibrosis, acute myeloid leukemia, or death) compared with best available therapy. pERC noted that the key limitation of the CONTINUATION-PV study was its enrichment study design by enrolling patients who demonstrated benefit in the PROUD-PV trial which might have resulted in the overestimation of efficacy and underestimation of harms.

Overall, the results of the matching-adjusted indirect comparison (MAIC) suggested that ropeginterferon alfa-2b may result in little to no difference in complete response at 24 and 36 months when compared with peginterferon alfa-2a. However, pERC noted that the indirect comparison was subject to considerable limitations and uncertainty preventing any firm conclusions to be made regarding comparative efficacy. pERC also noted that there remains a gap in the evidence regarding the efficacy and harms of ropeginterferon alfa-2b compared to other treatments commonly used in clinical practice in Canada.

Further information on the committee’s discussion around clinical value is provided in the Summary of Deliberation section.

Considering Significant Unmet Clinical Need

pERC also established that there is significant unmet clinical need for additional cytoreductive treatment options for PV. PV is a rare disease, as the incidence in Canada is estimated at around 2 per 100,000 per year. Untreated PV carries a potentially life-threatening risk of thrombosis and hemorrhagic complications. There is also the risk of progression to myelofibrosis and acute myeloid leukemia. pERC noted that there are currently limited treatment options available, and hydroxyurea, used off-label, is the most commonly used first-line cytoreductive treatment for these patients. Other treatment options include peginterferon alfa-2a which may not be available in all jurisdictions and ruxolitinib is available as a second-line treatment, after resistance or intolerance to hydroxyurea. In addition, hydroxyurea does not have disease modifying properties and does not target JAK2 mutation, where they have been identified as unmet needs by patients and clinicians. There is also the challenge where some patients develop intolerance or resistance to hydroxyurea; hydroxyurea is associated with unique toxicities such as development of mouth and skin ulcers, fatigue, myelosuppression, and increased risk of nonmelanoma skin cancer. Further, hydroxyurea is teratogenic and may not be suitable for those of reproductive age. Of note, the Health Canada product monograph for Hydrea (hydroxyurea) recommends that “female patients of reproductive potential should be counselled to use effective contraception during therapy and for at least 6 months after therapy” and “men under therapy are advised to use safe contraceptive measures during and at least 1 year after therapy.” The committee also acknowledged that the need for additional cytoreductive treatment options for PV may also be driven by supply shortages of both hydroxyurea and peginterferon alfa-2a in some jurisdictions and there is a significant unmet need, particularly for patients with intolerance or contraindications to hydroxyurea.

pERC concluded that ropeginterferon alfa-2b addresses a significant unmet need to a degree that justifies a positive recommendation despite the uncertainty in clinical value.

Further information on the committee’s discussion around unmet clinical need is provided in the Summary of Deliberation section.

Developing the Recommendation

Due to the uncertainty in clinical value, pERC could not recommend whether to reimburse ropeginterferon alfa-2b based on clinical value alone. Therefore, the committee also considered whether ropeginterferon alfa-2b addresses a significant unmet clinical need. pERC concluded that ropeginterferon alfa-2b addresses a significant unmet clinical need with an acceptable level of certainty. Based on the preceding considerations, pERC recommended that ropeginterferon alfa-2b be reimbursed. As part of the deliberation on whether to recommend reimbursement, the committee also considered unmet nonclinical need and health inequity. Information on this discussion is provided in the Distinct Social and Ethical Considerations domain in the Summary of Deliberation section.

Because pERC recommended that ropeginterferon alfa-2b be reimbursed, the committee also deliberated on whether reimbursement conditions should be added to address important economic considerations, health system impacts, or social and ethical considerations, or to ensure clinical value is realized. The resulting reimbursement conditions, with accompanying reasons and implementation guidance, are stated in Table 1.

Summary of Deliberation

pERC considered all domains of value of the deliberative framework before developing its recommendation: clinical value, unmet clinical need, distinct social and ethical considerations, economic considerations, and impacts on health systems. For further information on the domains of value, refer to Expert Committee Deliberation at Canada’s Drug Agency.

The committee considered the following key discussion points, organized by the 5 domains of value.

Clinical Value

Unmet Clinical Need

Distinct Social and Ethical Considerations

Economic Considerations

Impacts on Health Systems

Sources of Information Used by the Committee

To make its recommendation, the committee considered the following information (links to the full documents for the review can be found on the project web page):

All feedback received in response to the draft recommendation is available on the CDA-AMC project web page.

pERC Information

Members of the Committee

Dr. Catherine Moltzan (Chair), Dr. Kelvin Chan (Vice-Chair), Paul Agbulu, Dr. Phillip Blanchette, Dr. Matthew Cheung, Annette Cyr, Dr. Jennifer Fishman, Dr. Prafull Ghatage, Dr. Jason Hart, Terry Hawrysh, Dr. Yoo-Joung Ko, Dr. Aly-Khan Lalani, Amy Peasgood, Dr. Anca Prica, Dr. Michael Raphael, Dr. Adam Raymakers, Dr. Patricia Tang, Dr. Pierre Villeneuve, and Danica Wasney.

Meeting date: September 8, 2026

Regrets: Two expert committee members did not attend.

Conflicts of interest: One expert committee member did not participate due to considerations of conflict of interest.